We are now two standalone organizations
Life Sciences & Diagnostics and Analytical & Enterprise Solutions
A Life Sciences and Diagnostics business focused on enabling scientists and healthcare professionals to advance research, discovery and detection to improve global health
An Analytical and Enterprise solutions business, including leading OneSource laboratory services, focused on accelerating scientific outcomes
Immuno-oncology is an exciting area within cancer research and among the most promising approaches to activating therapeutic antitumor immunity is through the blockade of immune checkpoints. The programmed cell death-1 (PD-1) immune checkpoint pathway is a negative regulator of T cell immune function. When PD-1 is bound to programmed cell death-ligand 1 (PD-L1), T cell response is suppressed. Many tumor cells escape anti-tumor immunity through their expression of Programmed Death Ligand 1 (PD-L1 or B7-H1), which interacts with T cell-expressed PD-1 and results in T cell apoptosis. PD-L1 expression has been studied in multiple different cancers. While several anti-PD-1 or PD-L1 monoclonal antibodies that block the PD-1/ PD-L1 complex formation have been developed to date, there remains a need for more robust, rapid, high-throughput assays to identify and qualify novel inhibitors of PD-1/PD-L1 binding and assays to detect expression levels of both binding partners. Find out how LANCE® Ultra Technology provides a fast, powerful, homogeneous platform for identifying and characterizing endogenous PD-L1 and PD-1 expression in human cells.